Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. RLYB.NASDAQ

Rallybio Corp (RLYB NASDAQ) stock market data APIs

$1.36 0(0%) as of July 26, 2024
Price chart is built with Anychart

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Rallybio Corp Financial Data Overview

1.36
1.36
-
1.38
1.3301
1.155-6.33
55 957 K
41 449 K
0
-0.47
-1.687
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'RLYB',
Type: 'Common Stock',
Name: 'Rallybio Corp',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG011PFKF54',
ISIN: NULL,
CUSIP: NULL,
CIK: '1739410',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2021-07-29',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Rallybio Corp Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -76 899 000
  • Earnings Per Share -1.88
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Rallybio Corp Earnings via APIs

  • Latest Release 2024-05-07
  • EPS/Forecast -0.5

Get Rallybio Corp End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Rallybio Corp latest news via APIs

5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatmen...
  • 5AM VENTURE MANAGEMENT
  • HEALTH
  • LLC

EyePoint Pharma Takes $20.7M Intangible Impairment Charge In Q4, Shares Pipeline Update, Expects Cash Runway Into 2024

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported Q4 revenues of $10.5 million, down 8.8% Y/Y, almost in line with the consensus of $10.40 million. Non-operating income totaled $0.3 million, an...
  • CASH EQUIVALENTS
  • EYEPOINT
  • Q4 REVENUES
Do you have any questions?
support@eodhistoricaldata.com